undamentalytics Newsletter
Sign in

Mediwound Ltd. (MDWD) stock

Add to watchlist

Add holding +

NASDAQ: MDWD Nasdaq Biotechnology Next results ~November 12, 2026

Mediwound Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Mediwound Ltd. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders3 buying, 2 selling7 purchases and 4 sales by directors and officers, last 12 monthsInsider trades
  • Funds43 adding, 29 cuttingOf 6 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Mediwound files

Where Mediwound stands after its latest Filing

Revenue for the twelve months was $17m, down 16.1% on a year earlier, against growth of 8.2% a quarter earlier. Free-cash-flow margin fell to -127.5% from -39.6% a year earlier. Operating margin narrowed to -149.0% from -47.2%. The diluted share count is up 14.2% on a year earlier, which dilutes existing holders. It passes 2 of our 3 financial-health checks.

Our model value for Mediwound is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Mediwound Ltd.'s trailing-twelve-month revenue fell 16.1% year on year, with a free-cash-flow margin of -127.5%.

Current signal Net income rising while operating cash flow falls: TTM net income grew 21.0% while operating cash flow fell 18.3% — earnings and cash are telling different stories.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Revenue shrinking. Revenue fell 16.1% over the last 12 months.
  • Growth slowing. The growth rate is 24.4 points lower than a quarter earlier.
  • Loss-making. Operating margin is -149.0%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 53.0 points on a year ago.
  • Burning cash. Free cash flow was -127.5% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 18.3% of revenue: a real cost that cash-flow figures leave out.

Latest results

Earnings per share
-$0.57 against an average estimate of -$0.77: beat by 26.0%
Next report
November 12, 2026; average EPS estimate -$0.73

Mediwound's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.5%
  • 1 week+11.9%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$17M
Operating margin
-149.0%
Net margin
-140.8%
EPS (TTM, diluted)
$-2.10

Growth

Revenue growth
−16.1%
Change in growth rate
−24.4 pts
Share count change
+14.2%

Cash

Free cash flow (TTM)
-$21.6M
FCF margin
-127.5%
Stock pay % of revenue
18.3%

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for MDWD from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Mediwound Ltd. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Mediwound Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$7.6 ~$7.8–$29 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Mediwound Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $7m and EPS of −$0.73 (range −$0.92 to −$0.62) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.23 −6% $24m +40%
Next −$2.29 −3% $32m +34%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −6.5% on 90 days ago. In the last 30 days, 3 analysts raised Mediwound Ltd.'s forecast and 1 cut it.

Consensus EPS forecast Mediwound Ltd., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.38 Current fiscal year, 60 days ago: −$2.38 Current fiscal year, 30 days ago: −$2.23 Current fiscal year, 7 days ago: −$2.23 Current fiscal year, Now: −$2.23 −$2.23 Next fiscal year, 90 days ago: −$2.22 Next fiscal year, 60 days ago: −$2.22 Next fiscal year, 30 days ago: −$2.29 Next fiscal year, 7 days ago: −$2.29 Next fiscal year, Now: −$2.29 −$2.29

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.38−$2.22
60 days ago −$2.38−$2.22
30 days ago −$2.23−$2.29
7 days ago −$2.23−$2.29
Now −$2.23−$2.29

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.77 −$0.57 +26.0%
Mar 2026 −$0.66 −$0.23 +65.3%
Dec 2025 −$0.61 −$0.56 +8.5%
Sept 2025 −$0.83 −$0.24 +71.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

6 analysts, Nov 2026
Buy6100%
Hold00%
Sell00%

Monthly trend

  1. Nov 2026156
  2. Oct 2026156

Counts of recommendations published by analysts covering Mediwound Ltd., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
15.5%
of tradable shares
Days to cover
24.32
at average volume
Short interest, 1 month
−4%
to October 15, 2026
Held by institutions
56%
of shares
Held by insiders
16.8%
of shares
Employees
121
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Revenue (TTM) Mediwound Ltd.
$0 $10M $20M $30M $40M FY15 Q4 FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue (TTM), FY15 Q4: $601K Revenue (TTM), FY16 Q4: $1.6M Revenue (TTM), FY17 Q4: $2.5M Revenue (TTM), FY18 Q4: $3.4M Revenue (TTM), FY19 Q4: $31.8M Revenue (TTM), FY20 Q4: $21.8M Revenue (TTM), FY21 Q4: $23.8M Revenue (TTM), FY22 Q4: $26.5M Revenue (TTM), FY23 Q4: $18.7M Revenue (TTM), FY24 Q4: $20.2M Revenue (TTM), FY25 Q4: $17M $17M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY15 Q4 $601K
FY16 Q4 $1.6M
FY17 Q4 $2.5M
FY18 Q4 $3.4M
FY19 Q4 $31.8M
FY20 Q4 $21.8M
FY21 Q4 $23.8M
FY22 Q4 $26.5M
FY23 Q4 $18.7M
FY24 Q4 $20.2M
FY25 Q4 $17M
Revenue growth, TTM YoY Mediwound Ltd.
-500% 0% 500% 1000% FY16 Q4 FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 Revenue growth, TTM YoY, FY16 Q4: 159.2% Revenue growth, TTM YoY, FY17 Q4: 60.2% Revenue growth, TTM YoY, FY18 Q4: 36.3% Revenue growth, TTM YoY, FY19 Q4: 834.7% Revenue growth, TTM YoY, FY20 Q4: -31.5% Revenue growth, TTM YoY, FY21 Q4: 9.2% Revenue growth, TTM YoY, FY22 Q4: 11.5% Revenue growth, TTM YoY, FY23 Q4: -29.5% Revenue growth, TTM YoY, FY24 Q4: 8.2% Revenue growth, TTM YoY, FY25 Q4: -16.1% -16.1%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY16 Q4 159.2%
FY17 Q4 60.2%
FY18 Q4 36.3%
FY19 Q4 834.7%
FY20 Q4 -31.5%
FY21 Q4 9.2%
FY22 Q4 11.5%
FY23 Q4 -29.5%
FY24 Q4 8.2%
FY25 Q4 -16.1%
Operating margin (TTM) Mediwound Ltd.
-4000% -3000% -2000% -1000% 0% 1000% FY15 Q4 FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Operating margin (TTM), FY15 Q4: -3531.9% Operating margin (TTM), FY16 Q4: -1293.6% Operating margin (TTM), FY17 Q4: -548.4% Operating margin (TTM), FY18 Q4: -116.4% Operating margin (TTM), FY19 Q4: 14.1% Operating margin (TTM), FY20 Q4: -40.6% Operating margin (TTM), FY21 Q4: -47.2% Operating margin (TTM), FY22 Q4: -31.5% Operating margin (TTM), FY23 Q4: -81.8% Operating margin (TTM), FY24 Q4: -95.9% Operating margin (TTM), FY25 Q4: -149.0% -149.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY15 Q4 -3531.9%
FY16 Q4 -1293.6%
FY17 Q4 -548.4%
FY18 Q4 -116.4%
FY19 Q4 14.1%
FY20 Q4 -40.6%
FY21 Q4 -47.2%
FY22 Q4 -31.5%
FY23 Q4 -81.8%
FY24 Q4 -95.9%
FY25 Q4 -149.0%
FCF margin (TTM) Mediwound Ltd.
-4000% -3000% -2000% -1000% 0% 1000% FY15 Q4 FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 FCF margin (TTM), FY15 Q4: -3324.0% FCF margin (TTM), FY16 Q4: -1098.6% FCF margin (TTM), FY17 Q4: -701.1% FCF margin (TTM), FY18 Q4: -372.7% FCF margin (TTM), FY19 Q4: 23.6% FCF margin (TTM), FY20 Q4: -35.9% FCF margin (TTM), FY21 Q4: -39.6% FCF margin (TTM), FY22 Q4: -47.0% FCF margin (TTM), FY23 Q4: -90.6% FCF margin (TTM), FY24 Q4: -98.4% FCF margin (TTM), FY25 Q4: -127.5% -127.5%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY15 Q4 -3324.0%
FY16 Q4 -1098.6%
FY17 Q4 -701.1%
FY18 Q4 -372.7%
FY19 Q4 23.6%
FY20 Q4 -35.9%
FY21 Q4 -39.6%
FY22 Q4 -47.0%
FY23 Q4 -90.6%
FY24 Q4 -98.4%
FY25 Q4 -127.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 1 2 2 3 32 22 24 26 19 20 17
Gross profit −2 −1 1 1 20 8 9 13 4 3 3
EBITDA −21 −20 −13 −3 5 −8 −11 −8 −15 −19 −25
Operating income −21 −20 −14 −4 4 −9 −11 −8 −15 −19 −25
Net income −22 −19 −22 −1 5 −9 −14 −20 −7 −30 −24
Diluted EPS — — — — — −$16.66 −$3.48 −$3.93 −$0.75 −$3.03 −$2.10
Growth (year on year)
Revenue — +159.2% +60.2% +36.3% +834.7% −31.5% +9.2% +11.5% −29.5% +8.2% −16.1%
EBITDA — — — — — −268.9% — — — — —
Operating income — — — — — −296.8% — — — — —
Net income — — — — — −285.6% — — — — —
Margins
Gross margin −319.1% −38.5% 36.8% 38.6% 62.7% 34.7% 36.9% 49.7% 19.1% 13.0% 19.2%
EBITDA margin <−999% <−999% −530.0% −102.5% 15.7% −38.8% −44.9% −29.9% −78.2% −92.8% −145.5%
Operating margin <−999% <−999% −548.4% −116.4% 14.1% −40.6% −47.2% −31.5% −81.8% −95.9% −149.0%
Net margin <−999% <−999% −887.4% −31.1% 15.6% −42.3% −57.0% −74.0% −35.9% −149.5% −140.8%
Free-cash-flow margin <−999% <−999% −701.1% −372.7% 23.6% −35.9% −39.6% −47.0% −90.6% −98.4% −127.5%
Cash flow
Cash from operations −20 −16 −16 −12 8 −7 −9 −12 −10 −14 −16
Capital spending 0 1 1 1 1 1 0 1 6 6 6
Free cash flow −20 −17 −18 −13 7 −8 −9 −12 −17 −20 −22
Stock-based pay 3 3 1 1 1 1 2 2 2 3 3
Free cash flow after stock pay −23 −20 −19 −13 6 −9 −11 −14 −19 −23 −25
Balance sheet
Cash 43 29 36 7 7 17 11 34 12 9 5
Total debt 0 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −43 −29 −36 −7 −7 −17 −11 −34 −12 −9 −5
Diluted shares 3m 3m 3m 4m 4m 4m 4m 5m 9m 10m 11m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · December 31, 2025
What it owns · $86m
Short-term assets $60mLonger-term assets $26m
What it owes, and who funded it · $86m
Short-term liabilities $26mLonger-term liabilities $17mShareholders' equity $44m
  • Short-term assets cover short-term liabilities $60m of assets due within a year against $26m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $60m short-term assets against $17m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$25m against $625,000 of interest.

From Mediwound Ltd.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+14.2%
year over year
R&D spending
84.4%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated MDWD PRQR CTMX CELU SCYX KROS Median
Revenue, last 12 months $17m $18m $18m $19m $19m $15m $55m
Revenue growth, last 12 months −16.1% −12.1% −87.0% −58.1% 489.8% −93.6% 12.2%
Revenue growth, 3-year average — — −38.7% 7.2% −47.9% — 13.7%
Revenue growth, latest quarter — — −92.4% −5.3% −82.8% −100.0% 10.2%
Gross margin 19.2% — — 19.2% 26.0% — 82.8%
Operating margin −149.0% −273.1% −476.2% −264.3% −117.6% −682.3% −187.2%
Operating margin, 3-year average −248.2% — −146.9% −204.2% −592.1% <−999% −361.6%
Net margin −140.8% −265.2% −435.2% −245.7% −53.3% −559.2% −163.5%
Cash from operations / revenue −95.1% −331.9% −450.3% −47.8% −69.3% −322.7% −162.3%
Free-cash-flow margin −127.5% −338.3% −450.7% −80.1% −69.3% −326.1% −156.7%
Free-cash-flow margin, 3-year average −289.4% — −192.6% −50.3% −304.8% <−999% −306.5%
Stock pay / revenue 18.3% 25.2% 55.4% 66.5% 12.3% 153.8% 19.2%
Change in share count 14.2% 22.4% 88.7% 24.7% 1.9% −31.6% 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$85.5M
Institutions reporting
79
Shares held vs prior quarter
▼ 3.7%
Positions opened / closed
14 / 10

Top buyers and sellers, Q2 2026: 43 institutions bought and 29 sold ; the biggest buyer was Blackrock, Inc (+80K shares) and the biggest seller Meitav Investment House Ltd (−372K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Investor AB $12.8M 872K 15.0% 0.0%
Yelin Lapidot Holdings Management Ltd. $11.1M 758K 13.0% ▼ 0.6%
Rosalind Advisors, Inc. $11M 749K 12.9% 0.0%
Price T Rowe Associates Inc $9.4M 641K 11.0% ▼ 9.7%
Blackrock, Inc. $7.7M 526K 9.0% ▲ 18.0%
Sphera Funds Management Ltd. $4M 273K 4.7% 0.0%
Silverberg Bernstein Capital Management LLC $3.4M 228K 3.9% ▲ 14.1%
State Street Corp $2.5M 169K 2.9% ▲ 17.3%
UBS Group AG $2.3M 156K 2.7% ▼ 2.4%
Geode Capital Management, LLC $2.1M 141K 2.4% ▲ 15.6%
Point72 Asset Management, L.P. $1.9M 129K 2.2% ▼ 26.3%
ARK Investment Management LLC $1.9M 127K 2.2% ▼ 2.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Mediwound Ltd.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $142,690 7 trades by 3 insiders, last 12 months Insider sales History → $82,080 4 trades by 2 insiders · 0% under pre-set plans
Net ▲ $60,610 net buying
Insider Date Trade Shares Price Value
Rubinstein Samuel Director September 1, 2026 Sell 525 $12.72 $6,678
Rubinstein Samuel Director September 1, 2026 Buy 525 $12.62 $6,626
Hess Shmuel COO & Chief Commercial Officer August 27, 2026 Sell 1,979 $12.72 $25,173
Hess Shmuel COO & Chief Commercial Officer August 27, 2026 Sell 1,979 $13.13 $25,984
Hess Shmuel COO & Chief Commercial Officer August 26, 2026 Sell 1,865 $13.00 $24,245
Shamir Nachum Director June 3, 2026 Buy 5,825 $14.00 $81,550
Shamir Nachum Director June 3, 2026 Buy 175 $13.98 $2,446
Fox David Morton Director June 1, 2026 Buy 1,797 $14.00 $25,158
Fox David Morton Director June 1, 2026 Buy 10 $14.23 $142
Fox David Morton Director June 1, 2026 Buy 1,730 $14.23 $24,618
Rubinstein Samuel Director May 29, 2026 Buy 150 $14.33 $2,150

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Mediwound Ltd. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Mediwound Ltd. in brief

What does Mediwound Ltd. do?
Mediwound Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Mediwound Ltd.'s stock ticker?
Mediwound Ltd. trades under the ticker MDWD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Mediwound Ltd.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Mediwound Ltd. reported revenue of $17M, 16.1% lower than a year earlier, according to its SEC filings.
What is Mediwound Ltd.'s free cash flow?
Mediwound Ltd.'s free-cash-flow margin is -127.5% of revenue over the trailing twelve months.
Who are Mediwound Ltd.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Investor AB, Yelin Lapidot Holdings Management Ltd. and Rosalind Advisors, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Who are Mediwound Ltd.'s competitors?
In our Biotechnology peer group, the companies closest to Mediwound Ltd. are Proqr Therapeutics N.V., Cytomx Therapeutics, Inc., Celularity Inc, Scynexis Inc and Keros Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Mediwound Ltd.'s.
Are insiders buying or selling Mediwound Ltd. stock?
Over the last 12 months, Mediwound Ltd.'s directors and officers reported 7 open-market purchases and 4 sales on Form 4. The insider trading page charts every trade.
When is Mediwound Ltd.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Mediwound Ltd. announces its own schedule.